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Abstract: Background: Case reports are usually excluded from systematic reviews. Patients with rare
diseases are more dependent on novel individualized strategies than patients with common diseases.
We reviewed and summarized the novelties reported by case reports in mucopolysaccharidosis type
II (MPS-II) patients treated with enzyme replacement therapy (ERT). Methods: We selected the case
reports included in a previous meta-analysis of patients with MPS-II treated with ERT. Later clinical
studies evaluating the same topic of those case reports were reported. Our primary aim was to
summarize novelties reported in previous case reports. Secondary objectives analyzed the number
of novelties evaluated in subsequent clinical studies and the time elapsed between the publication
of the case report to the publication of the clinical study. Results: We identified 11 innovative
proposals in case reports that had not been previously considered in clinical studies. Only two (18.2%)
were analyzed in subsequent nonrandomized cohort studies. The other nine novelties (81.8%) were
analyzed in later case reports (five) or were not included in ulterior studies (four) after more than
five years from their first publication. Conclusions: Case reports should be included in systematic
reviews of rare disease to obtain a comprehensive summary of the state of research and offer valuable
information for healthcare practitioners.
Keywords: systematic review; meta-analysis; randomized clinical trial; nonrandomized study; case report;
mucopolysaccharidosis; enzyme replacement therapy; rare disease; clinical studies
1. Introduction
Rare diseases and ultra-rare diseases are defined by a prevalence of ≤50 patients and ≤1 patient per
100,000 people, respectively. This low prevalence of such diseases makes the conduction of randomized
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and prospectively designed studies very hard [1,2]. As an example, mucopolysaccharidosis type II
(MPS-II) has a prevalence of 1 in 140,000–156,000 patients [3]. In this case, the registries of clinical cases
usually are the best option for clinical research [4,5]. Furthermore, in rare diseases, the phenotype and
genotype heterogeneity limit the generalization of the data from clinical trials to clinical practice [1,6].
Thus, pharmacological treatment of patients with orphan and ultra-orphan drugs is more dependent
on individualized strategies than treatment of more prevalent diseases [7,8].
The value of case reports as individual studies has been stated in previous reviews [9]. Investigators
have considered that case reports are appropriate to report new clinical findings, generating new
hypothesis about pharmacological therapies, educational value, and high applicability in situations
where other designs are not feasible. However, case reports are limited by their retrospective,
nonblinded, and nonrandomized trial design, constituting a source of biases that could affect the study
outcome. Therefore, findings provided by case reports might not be generalizable and could not be
useful to establish a cause–effect relationship, with a consequent high risk of over-interpretation [9–11].
Accordingly, it is uncommon to include case reports in systematic reviews and meta-analyses [12,13].
Systematic reviews were developed to ensure that decisions affecting human health would be
informed with the complete understanding of the most relevant research evidence. Thus, the purpose
of a systematic review is to provide a summary of the state of research knowledge on an intervention,
diagnostic test, prognostic factor, or other health or healthcare topics [12]. It has been suggested that
novelties about available interventions are published in case reports five or more years earlier than in
clinical studies [13]. Accordingly, a detailed review of a health topic should not exclude published
clinical reports, especially in the field of rare diseases, where the individualization of treatments or
management strategies has a great relevance on clinical practice [14,15].
A systematic review evaluating the efficacy and safety of enzyme replacement therapy (ERT) for
treatment of patients with MPS-II has been previously published [2]. The aim of the present study was
to review the novelties on outcomes or therapeutic strategies reported in case studies of the mentioned
systematic review [2]. Secondary objectives included the number of novelties evaluated in subsequent
clinical studies and the time elapsed between the publication of a novelty in a case report and its
subsequent inclusion in a clinical study. Consequently, we searched for the latest clinical studies that
incorporated the research questions stated by previous case reports.
2. Methods
2.1. Data Sources, Study Selection, and Quality Assessment from the Previous Meta-Analysis of Case Reports
The case reports selected were previously included in a recent meta-analysis by Sampayo-Cordero
M. et al. [2]. The systematic review included case reports of MPS-II patients who were treated with ERT,
and the search was carried out in Excerpta Medica Database (EMBASE), Medical Literature Analysis
and Retrieval System Online (MEDLINE), The Cochrane Library (Cochrane Database of Systematic
Reviews, Cochrane Central Register of Controlled Trials, and Cochrane Methodology Register and
Health Technology Assessment Databases), as well as on the Latin American and Caribbean Literature
on Health Sciences (LILACS). The search methods, study selection, and quality assessment are deeply
described in the mentioned publication [2]. All case reports published up to 31 December 2015 were
included in the search. For the current study, we selected all case reports that evaluated a new outcome
or a new therapeutic strategy with ERT in MPS-II patients. Case reports excluded objectives that were
similar to those described in previous randomized and nonrandomized studies [16–20].
2.2. Data Search of New Clinical Studies
The case reports selected from the previous meta-analysis were used to search new clinical studies with
the same issue. We searched for the most recent clinical studies that incorporated the novelties proposed
by case reports in patients with MPS-II treated with ERT. We searched MEDLINE and GOOGLE (all)
for case reports that reported these novelties and retrieved the citations included in sections “cited by”
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or “comment”. There was no restriction of dose, treatment duration, administration via (intravenous or
intrathecal), type of study design, or language. All published studies up to 1 July 2020 were included in our
comprehensive search.
2.3. Study Selection
We selected all clinical studies citing the original case report, which accomplished the following
selection criteria:
Inclusion criteria:
(1) Clinical studies (randomized or nonrandomized) and case reports of patients with MPS-II treated
with ERT.
(2) The study design evaluates as primary, secondary, or exploratory objective the novelty proposed
by the case report.
(3) The results reported included data from new patients where the novelty was the object of research.
Exclusion criteria:
(1) Clinical studies or case reports in other diseases or based on treatment without ERT.
(2) Systematic or literature reviews that do not include analyses of new patients.
2.4. Quality Assessment
The study was prospectively designed to select the studies that analyzed the novelties proposed by
previous case reports on MPS-II. Results of current meta-analysis are reported in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) and Meta-Analyses
and Systematic Reviews of Observational Studies (MOOSE) guidelines [21,22]. Three investigators
(M.S.-C., B.M.-H., and A.P) entered findings into a database, independently reviewed citations/abstracts
from the database, and hand searched and selected full relevant articles and documents for data
extraction using preset criteria. Discrepancies were resolved through discussion or input from a fourth
reviewer (J.P.-L.).
2.5. Primary Outcome
The primary outcome was a synthetic description of novelties proposed by the case reports that
were selected in the meta-analysis of Sampayo-Cordero M. et al. [2]. We compared the objectives
and ERT schedules of each selected case report with those of clinical studies published prior to the
meta-analysis [16–20]. The case reports with objectives or therapy strategies equal to those of the
clinical studies were not considered. Only the case reports analyzing novel objectives and therapy
strategies were described.
2.6. Secondary Outcomes
A. The number of novelties proposed by prior case reports evaluated in subsequent clinical studies.
The subsequent clinical studies were reported by type of study (randomized, cohort study, and case
report).
B. The time between the publication of the case report and the clinical study.
2.7. Statistical Methods
Novelties described in each case report were summarized in a narrative format. The number of
novelties and clinical studies was reported as number and percentage. The time elapsed between the
publication of a case report including a specific novelty and the follow-up clinical study or studies was
calculated subtracting the date of the first clinical study to the date of the first case report analyzing
such novelty. If there was not a clinical study analyzing that novelty, the cutoff date was 1 July 2020.
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3. Results
3.1. Data Search Results
An accurate selection of case reports with novelties published by Sampayo-Cordero et al. [2],
which included publications through 31 December 2015, identified 27 citations [2]. Of 27 studies
identified, 11 were excluded because they evaluated objectives and ERT schedules equivalent to those
of previous clinical studies [16–20]. Thus, 16 publications of case reports were included in the study
and their summary identified 11 different novelty proposals about ERT in MPS-II patients (primary
objective).
Searching for these 16 case reports, we identified 72 following publications. However, 11 of 72
publications analyzed the novelties of these case reports, while the remaining 61 publications were
excluded because they did not (see Supplementary Table S1 and Figure 1).
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3.2. Primary Outcome
Our study identified 11 innovative proposals in case reports that had not been previously
considered in clinical studies. Most of them evaluated the efficacy of ERT in different outcomes and
therapeutic situations compared with those included in previous clinical studies. They considered skin
lesions, hyperactivity, aggressive behavior, language functioning, social interaction, central nervous
system development, epileptogenic symptoms, effects in vision, and bone abnormalities. In addition,
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some case reports evaluated the efficacy of ERT in patients with physical abnormalities or affected
by hematological diseases. Finally, three studies suggested new therapeutic strategies to increase the
immunotolerance for ERT and to reduce dermatan sulfate in plasma (see Table 1) [23–25].
Table 1. Novelties proposed in case reports for enzyme replacement therapy in mucopolysaccharidosis
type II patients.
Novelties Proposed in Case Reports for Treatment of MPS-II
Patient with ERT * Case Reports Selected
New therapeutic strategies to increase the immunotolerance for ERT
(1) Immune tolerance regimen and desensitization procedures Kim et al. 2014; Gkavogiannakis N et al.2015 [23,24]
(2) New therapeutic strategies based on the evaluation of
plasmatic dermatan sulfate Volpi et al. 2013 [25]
Different outcomes and therapeutic situations
(3) Effects in pebbling skin lesions NoH et al. 2014; Marín LL et al.2012 [26,27]
(4) Effects in hyperactivity, aggressive behavior, language
functioning, and social interaction Puiu M et al. 2013 [28]
(5) Evaluation of the effects of ERT in central nervous system
development Wang RY et al. 2009 [29]
(6) Evaluation of the effects of ERT in epileptogenic symptoms Kinoshita M et al. 2014; Bonanni P et al.2012 [30,31]
(7) ERT effects in vision Sanchez JI et al. 2015; Lau HA et al.2015 [32,33]
(8) ERT effect in autoimmune anemia, thrombocytopenia, or
thrombocytopenic purpura Fisher et al. 2015; Uz B et al. 2012 [34,35]
(9) Botulinum Toxin for the treatment of equinus deformity with
an ERT Nava E et al. 2012 [36]
(10) ERT effects in involuntary movements (chorea) Farooq MU et al. 2008 [37]
(11) Early ERT effects in bone abnormalities Papadia F et al. 2011 [38]
ERT—enzyme replacement therapy, MPS-II—mucopolysaccharidosis type II. *—Only case reports reporting novelties
were analyzed. Case reports excluded analyzed objectives similar to those described in previous randomized
and nonrandomized studies (Muenzer et al. 2006, Muenzer et al. 2011, Tolar J. et al. 2008, Wynn F. et al. 2009,
and Eisengart J.B. et al. 2013) [16–20]. The case reports excluded were: Lampe et al. 2014, Biviana et al. 2014,
Christiano et al. 2013, Sato et al. 2013, Tajima et al. 2013, Hoffmann B. et al. 2011, Tylki-Szymanska et al. 2012,
Pérez-Calvo et al. 2011, Tchan M.C. et al. 2011, Westhoff M. et al. 2011, and Galán Gómez E. et al. 2008 [39–49].
3.3. Secondary Outcomes
Of 11 novelties, only two (18.2%) were analyzed in subsequent cohort studies: (1) The efficacy of
early ERT in central nervous system and (2) bone abnormalities. The other nine novelties (81.8%) were
analyzed in later case reports (five novelties) or were not included in ulterior studies (four novelties).
The five novelties evaluated in new case reports were: (1) The immune tolerance regimen, (2) the effect
of ERT in skin, (3) the effect of ERT in epileptogenic symptoms, (4) the effect of ERT in ocular function,
and (5) the effect of ERT in hematological diseases. So, novelties proposed in case reports are usually
confirmed with later case reports. None of the proposed innovations was included in the objectives of
a subsequent randomized clinical trial. In most cases, novel strategies suggested in case reports were
not evaluated in a cohort or randomized study after 5 to 12 years (see Table 2).
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Table 2. Clinical studies evaluating novelties proposed by prior case reports.
Novelties Proposed in Case Reports for
ERT in MPS-II Patients (Citation) *





(1) Immune tolerance regimen and
desensitization procedures [23,24]
Case report
(Julien DC et al., 2020) [50]
No clinical study
after 6 years
(2) New therapeutic strategies based on the
evaluation of plasmatic dermatan sulfate [25] No new citations
No clinical study
after 7 years
(3) Effects in pebbling skin lesions [26,27] Case report(Srinivas SM et al., 2017) [51]
No clinical study
after 8 years
(4) Effects in hyperactivity, aggressive
behavior, language functioning, and social
interaction [28]
No clinical study after 7 years No clinical studyafter 7 years
(5) Evaluation of the effects of ERT in central
nervous system development [29]
Cohort studies
Matsubara et al., 2017; Manara et al.,
2011 **; Yund et al., 2015; Tanaka A
et al., 2012
(3 case reports)
Crowe et al., 2017 [52–56]
2 years/Not
randomized
(6) Evaluation of the effects of ERT in
epileptogenic symptoms [30,31]
Case report
Scarpa et al., 2017
Bonanni et al., 2014 [57,58]
No clinical study
after 8 years
(7) ERT effects in vision [32,33] Case report(Yamanishi R et al., 2019) [59]
No clinical study
after 5 years




(Alcántara-Ortigoza et al., 2016) [60]
No clinical study
after 8 years
(9) Botulinum Toxin for the treatment of
equinus deformity with an ERT [36] No new citations
No clinical study
after 8 years
(10) ERT effects in involuntary movements
(chorea) [37] No new citations
No prospective study
after 12 years
(11) Early ERT effects in bone
abnormalities [38]
Cohort study
(Manara R et al., 2011 **) [53]
4 months/Not
randomized
ERT: Enzyme replacement therapy, MPS-II: Mucopolysaccharidosis type II. * Only case reports reporting novelties
were analyzed. Case reports excluded analyzed objectives similar to those described in previous randomized and
nonrandomized trials (Muenzer et al. 2006, Muenzer et al. 2011, Tolar J. et al. 2008, Wynn F. et al. 2009, and Eisengart
J.B. et al. 2013 [16–20]). The case reports excluded were: Lampe et al. 2014, Biviana et al. 2014, Christiano et al. 2013,
Sato et al. 2013, Tajima et al. 2013, Hoffmann B. et al. 2011, Tylki-Szymanska et al. 2012, Pérez-Calvo et al. 2011,
Tchan M.C. et al. 2011, Westhoff M. et al. 2011, and Galán Gómez E. et al. 2008 [39–49]. ** This study analyzed two
novelties proposed by previous case reports.
4. Discussion
In the last years, the interest in case reports by clinical research community as well as the
number of journals that publish case reports have increased rapidly [61]. Clinical cases’ journals
have been included in the Medline database for medical journals and registries of case reports have
been developed [9]. The greatest advantages of clinical cases are represented by their ability to
detect novelties, the generation of new hypotheses, and their usefulness in the investigation of rare
diseases [9]. Additionally, the individualization of therapies and management strategies is a key
factor to successfully treat patients with rare diseases. So, new proposals dealing with uncommon
situations in the treatment of rare-disease patients have great relevance to translate clinical research
into clinical practice [7,8]. One of the aims of systematic reviews on therapeutic interventions is to
summarize the state of art in this intervention [12]. However, case reports are systematically excluded
in systematic reviews in rare-disease research, especially when other designs with a higher level of
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evidence are included [12,15,62–65]. Therefore, important innovations, which could contribute to
a better management of the patient treated with orphan drugs, are systematically excluded from
systematic reviews of rare diseases [2,13].
Our results on MPS-II patients treated with ERT showed that case reports reported findings
relevant to complement patient management. The efficacy of ERT was explored on key outcomes (social
behavior, skin lesions, central nervous system development, bone abnormalities, visual acuity) and
specific situations (serious respiratory impairment, hematological disease, and physical abnormalities)
that had not been considered in previous clinical studies. Additionally, case reports also proposed
new therapeutic strategies to deal with immune reactions against ERT [23–38,49]. In accordance with
previous results, we observed that most of these novelties were not assessed in subsequent clinical
studies after five years from the publication of the case report [13]. Importantly, the new studies
assessing these proposals were usually case reports [31,50,51,57,59,60]. Therefore, the evidence and
innovations provided by case reports will take a long time to be incorporated into clinical studies on
rare diseases [13].
Some previous systematic reviews in MPS have included case reports with clinical studies [2,13–15].
As we observed in our results, the inclusion of case reports was necessary to complete the evaluation
of the ERT profile in specific situations (pregnancy, ERT discontinuation, surgery interventions,
recovering from cerebral infarctions, serious respiratory impairment, or hematological diseases),
key alternative outcomes (frequency of respiratory infections, texture of hair and/or skin, skeletal
disease, or disease-related hospitalizations), and alternative therapeutic strategies with ERT [2,13–15].
Additionally, the inclusion of case reports allows us to assess the heterogeneity between the patients
included in clinical studies and those from clinical cases; and it is useful to evaluate if ERT efficacy
and safety results are equivalent among different study designs. The inclusion of case reports allows
including all available evidence on ERT and it could increase the power of analyses performed [2,13–15].
We observed in previous systematic reviews including case reports that they used two alternative
strategies. The first proposal summarized the results of the case reports and discussed them qualitatively.
The results from case reports were not included in meta-analyses [14,15]. The second method aggregated
the results of case reports in a meta-analysis. The strategy to analyze the results was to define two
improvement (or impairment) criteria. One for individual patients included in the meta-analyses (e.g.,
increase in 6-min walk test over the baseline assessment) and another for the specific outcome or group
of patients evaluated (e.g., a significant difference versus a 5% null hypothesis in the rate of patients
with improvement in the walk test) [2,13]. Both methodologies represent an advantage with respect to
excluding clinical cases from systematic reviews, since they allow enriching the study’s results and
conclusions [2,13–15]. Importantly, these studies have demonstrated that standardization and a good
definition of outcomes evaluated in case reports increase the validity of their results [2,13]. Therefore,
the tools to assess the quality of case reports and case series are very relevant in systematic reviews that
include clinical cases [66]. Different efforts have been done to homogenize and upgrade the quality of
case reports [67] or to search for case reports in clinical databases [9,68].
Previous studies and guidelines have considered that clinical cases could be included in systematic
reviews [2,13,69]. However, they do not consider the exclusion of case reports a serious concern if
there are other designs available. Case report exclusion from systematic reviews in rare diseases has
a greater impact than just the loss of a few cases with rare conditions or rare adverse events [12,69].
In fact, our analyses show that most of the novelties proposed in case reports are not subsequently
contrasted in clinical studies with more patients (after 5 to 12 years), which might be due to the case
reports being overlooked, since they are not included in reviews.
Our study took advantage of a previous systematic review to select the individual case reports
analyzed in this communication. We considered that this strategy provides an important quality
control measure. The selection procedures was previously accepted after a peer review revision [2].
An important point in our strategy for data search was retrieving articles, which cited selected
case reports. Some articles could have analyzed novelty of a case report without citing it. However,
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in rare diseases, and in MPS-II disease specifically, the number of clinical studies is quite limited, so it
is not likely to happen in many communications [62]. In addition, our study only included case reports
from MPS-II patients. Therefore, it is not clear whether the results obtained in this study could be
extrapolated to other rare diseases, although it is important to note that the methods for aggregating
clinical cases obtained similar results in different MPS, namely MPS-I and MPS-II [2,13–15].
It is usually considered that a MEDLINE search alone is not adequate for answering relevant
questions [12]. In accordance, we have increased the scope of our search with GOOGLE searcher,
since it is commonly used in all types of searches and has specific tools for systematic reviews and
scientific searches [70,71].
5. Conclusions
Different authors have underlined the impact of individual clinical reports’ results in clinical
practice and research [11,72]. Previous studies and guidelines have suggested the inclusion of case
reports in systematic reviews, but they did not consider the exclusion of case reports a serious concern
if there are other designs available with a higher grade of evidence than case reports [12,69]. However,
according to our results, most of the novel procedures proposed in case reports are not evaluated in
later clinical studies. Thus, case reports should be included in systematic reviews of rare diseases to
make a complete summary of the state of research, since excluding relevant novelties proposed in case
reports could reduce the usefulness of the review for clinical practice.
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